BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

Core Insights - BridgeBio Pharma, Inc. is hosting an investor webinar on September 10, 2025, focusing on its Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1) [1][2] - Dr. Rachel Gafni will discuss the pathophysiology of ADH1, the unmet medical needs, and the rationale for evaluating encaleret as a treatment [2] - The ongoing CALIBRATE study is expected to provide topline results in fall 2025 [2] Company Overview - BridgeBio Pharma is a biopharmaceutical company established to develop transformative medicines for genetic diseases, with a pipeline that includes early science to advanced clinical trials [4] - Founded in 2015, the company aims to leverage advances in genetic medicine to expedite patient treatment [4] Webinar Access - The investor webinar can be accessed via the "Events & Presentations" section on BridgeBio's website, with a replay available for 30 days post-event [3]